Research Sizes Global Markets, Measures Burden of Illness, Builds Evidence Package for Pre-Launch Rare Lung Disease Treatment
•Situation: A client developing a treatment for pulmonary nontuberculous mycobacterial (PNTM) disease, a rare lung infection, sought to size the market and understand the treatment landscape in
the US, Canada, Europe and Japan.
•The client also sought to build an evidence package to persuade regulators and
payors of the need for and value of its prospective orphan drug, via a subsequent
representative, 4-nation burden of illness (BOI) study of refractory patients and a
strong presence in medical literature and at medical/health outcomes conferences.